TherapeuticsMD (TXMD) Net Income towards Common Stockholders (2010 - 2026)
TherapeuticsMD (TXMD) reported Net Income towards Common Stockholders of -$8000.0 for Q1 2026, up 52.94% on a YoY basis from -$5230.8 in Q1 2025, and down 14.29% quarter-over-quarter from -$7000.0 in Q4 2025.
TherapeuticsMD (TXMD) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
TherapeuticsMD has reported Net Income towards Common Stockholders for 17 years, with the latest figure at -$8000.0 in Q1 2026.
- For the quarter ending Q1 2026, Net Income towards Common Stockholders rose 52.94% year-over-year to -$8000.0; the trailing twelve-month figure through Mar 2026 stood at $93000.0 (up 138.46% YoY), and the FY2025 full-year result was $84000.0, down 35.88% from the prior year.
- Net Income towards Common Stockholders for Q1 2026 stood at -$8000.0, down from -$7000.0 in the prior quarter.
- The five-year high for Net Income towards Common Stockholders was $127.2 million in Q2 2022, with the low at -$31.1 million in Q1 2022.
- Historically, Net Income towards Common Stockholders has averaged $6.8 million across 5 years, with a median of -$7500.0 in 2025.
- Annual changes were most pronounced in 2022 — Net Income towards Common Stockholders soared 398.12% — and 2025, when it slumped 122.67%.
- TherapeuticsMD's Net Income towards Common Stockholders stood at $29.2 million in 2022, then plunged by 97.75% to $658000.0 in 2023, then sank by 79.03% to $138000.0 in 2024, then plunged by 105.07% to -$7000.0 in 2025, then decreased by 14.29% to -$8000.0 in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$8000.0 (Q1 2026), -$7000.0 (Q4 2025), and $102000.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 366.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 1.99 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | TherapeuticsMD | 21,527.64 | -8.40 Mn | - | -8,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -8,000.00 |
| Dec 31, 2025 | -7,000.00 |
| Sep 30, 2025 | 102,000.00 |
| Jun 30, 2025 | 6,000.00 |
| Mar 31, 2025 | -17,000.00 |
| Dec 31, 2024 | 138,000.00 |
| Sep 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -40,000.00 |
| Mar 31, 2024 | 75,000.00 |
| Dec 31, 2023 | 658,000.00 |
| Sep 30, 2023 | -1.94 Mn |
| Mar 31, 2023 | -1.29 Mn |
| Dec 31, 2022 | 29.25 Mn |
| Sep 30, 2022 | -14.33 Mn |
| Jun 30, 2022 | 127.15 Mn |
| Mar 31, 2022 | -31.15 Mn |
| Dec 31, 2021 | 50.15 Mn |
| Sep 30, 2021 | -47.42 Mn |
| Jun 30, 2021 | -42.65 Mn |
| Mar 31, 2021 | -39.38 Mn |